Mornex F, Partensky C, Bedenne L
Département de radiothérapie-oncologie, EA 643, centre hospitalier Lyon-Sud, Pierre-Bénite, France.
Cancer Radiother. 1997;1(5):542-6. doi: 10.1016/s1278-3218(97)89636-9.
The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 10% of patients. Following surgery, the median survival is 12 months for the most favorable patients. Concomitant chemoradiation, as an adjuvant treatment is superior to surgery alone, in terms of survival, controlled trials are currently performed. Neoadjuvant chemoradiation is a new approach, potentially able to increase survival and resection rate. This work justifies the role of these schemes, in terms of modalities and potential advantages.
胰腺腺癌的预后仍然很差，5年生存率低于5%。手术切除作为金标准治疗方法，仅不到10%的患者能够进行。术后，最有利的患者中位生存期为12个月。同步放化疗作为辅助治疗优于单纯手术，目前正在进行对照试验。新辅助放化疗是一种新方法，有可能提高生存率和切除率。这项工作从方式和潜在优势方面证明了这些方案的作用。
